The FDA authorization has also been endorsed by Rochelle Walensky, MD, director of the CDC, according to a Dec. 9 agency news release.
Pfizer requested Nov. 30 that the FDA authorize the booster of its mRNA COVID-19 vaccine for 16- and 17-year-olds. The FDA’s decision followed the release of new data suggesting boosters might play a critical role protecting against the omicron variant.
“Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Janet Woodcock, MD, acting commissioner of the FDA, said in a Dec. 9 news release. “With both the delta and omicron variants continuing to spread, vaccination remains the best protection against COVID-19.”
As of Dec. 9, the Moderna and Johnson & Johnson vaccines are not authorized for anyone younger than 18.
More research is required before a decision is made about boosters for younger children, according to scientists.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
